Global Pet Weight Loss Medicines and Supplements Market Strategic Research Report

Scope of the Report

The global Pet Weight Loss Medicines and Supplements market size is predicted to grow from US$ 0.64 million in 2025 to US$ 20.31 million in 2032; it is expected to grow at a CAGR of 6.4% from 2026 to 2032.

Pet Weight Loss Medicines and Supplements refer to medications used for the management of overweight and obesity in dogs, cats, and other companion animals, as well as veterinary-guided weight management functional preparations. Their goals are to reduce body fat and weight, improve body condition scores (BCS), and reduce the risk of obesity-related complications. Product forms typically include oral solutions, tablets/capsules, soft chewable tablets, and powder strips; their mechanisms of action may include inhibiting fat absorption and transport, regulating appetite and energy intake, and improving metabolism and gut microbiota. From the demand side, the number of cats owned by urban households in China is large, but there are currently no approved prescription weight loss drugs, leaving the market untapped and offering a significant first-mover advantage. From a willingness-to-pay perspective, pet owners in first-tier and new first-tier cities spend an average of 2,000-3,000 yuan annually on medical care, showing a high acceptance of high-value-added products. Furthermore, obesity in cats easily leads to complications such as diabetes and arthritis, making treatment relatively inelastic. Regarding pet owners' acceptance of weight loss drugs, awareness education is a key bottleneck. Secondly, the usage scenarios are limited by the penetration rate of medical services; currently, only a small number of pets undergo regular checkups, restricting drug accessibility. However, whether it can achieve large-scale sales depends on three hurdles: pricing (if a single course of treatment is too expensive, most owners will opt to "skip a few meals"), education (pet hospitals and owners need to be convinced that "medication + diet management" is safer and more effective than simply dieting), and education. Most companies are currently in the research and development stage.

Pet obesity is rapidly shifting from a "feeding habit problem" to a "quantifiable health management problem." Rising companion animal healthcare spending and changes in the pet population's demographics are expanding weight management goals beyond simple weight loss to include joint reduction, improved metabolic indicators, and control of chronic disease risks. For brands, the value of weight-loss drugs and weight management formulations lies not only in individual product sales but also in forming repurchaseable, customized solutions that combine them with weight management food, body condition assessments, follow-up visits, and exercise and feeding plans, resulting in more stable lifetime revenue.

On the supply side, the limited number of prescription anti-obesity drugs specifically for pets, coupled with high compliance and safety requirements, along with owner compliance and weight rebound issues, makes it difficult to scale up the "single-drug solution" approach. Therefore, the market is more likely to expand along two lines: one is the trend towards lighter prescriptions and e-commerce, primarily using supplements and functional formulations, emphasizing safety boundaries and long-term use; the other is veterinarian-centric prescription and solution-based approaches, creating tiered management around high-risk dogs and cats, and improving sustainability through digital follow-up and subscription-based supplementation.

The structural trend on the demand side is that weight management is increasingly resembling a cross-category service-oriented consumption. Consumers are more willing to pay for visible improvements in their physical condition, and the distribution channels will see a combination of "online repurchase and replenishment plus offline veterinary assessment." At the same time, competition surrounding the scientific evidence for formulations, clinical follow-up data, and real-world effects will intensify significantly, and products lacking evidence or making exaggerated claims will face higher compliance and reputation risks.

Key Questions Addressed in this Report

What is the 10-year outlook for the global Pet Weight Loss Medicines and Supplements market?

What factors are driving Pet Weight Loss Medicines and Supplements market growth, globally and by region?

Which technologies are poised for the fastest growth by market and region?

How do Pet Weight Loss Medicines and Supplements market opportunities vary by end market size?

How does Pet Weight Loss Medicines and Supplements break out by Type, by Application?

This report presents a comprehensive overview of the global Pet Weight Loss Medicines and Supplements market, covering market size and forecast, segmentation by product type and application, competitive landscape, leading players and regional and country-level outlook.

Segment by Type

• Injectables
• Oral Medications
• Others

Segment by Pet

• Dogs
• Cats
• Others

Segment by Property

• Medicines
• Supplements

Segment by Application

• Pet Hospital
• Clinic

Who Can Use This Report?

This report is written for decision-makers who need a clear, data-backed view of the global Pet Weight Loss Medicines and Supplements market:

• Manufacturers, suppliers and solution providers benchmarking their position and planning product, capacity and go-to-market strategy
• Distributors, channel partners and end users in Pet Hospital, Clinic evaluating demand and sourcing options
• Investors, financial analysts and consultants assessing growth opportunities, competitive dynamics and M&A potential
• Government agencies, industry associations and research institutions tracking industry developments and policy impact